Αρχειοθήκη ιστολογίου

Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174

Παρασκευή 21 Δεκεμβρίου 2018

Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer

Conditions:   Clinical Stage II Esophageal Adenocarcinoma AJCC v8;   Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions:   Drug: Atezolizumab;   Procedure: Conventional Surgery;   Drug: Fluorouracil;   Drug: Oxaliplatin
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting

http://bit.ly/2EEL32b

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου